We have located links that may give you full text access.
Evans syndrome. Results of a pilot study utilizing a multiagent treatment protocol.
Journal of Pediatric Hematology/oncology 1995 November
PURPOSE: We evaluate the efficacy of combination medical therapy in the treatment of ITP and AIHA episodes for patients with Evans syndrome.
PATIENTS AND METHODS: Five patients with Evans syndrome were followed for a median of 3.8 years and were treated according to our multiagent (IVIG, steroids, vinca alkaloids, androgens, and cyclosporin) protocol.
RESULTS: All patients initially received IVIG and IV steroids for either acute hemolysis or thrombocytopenia. IV vinca alkaloids and oral Danazol were added in three patients for ITP. All responded, but two required frequently repeated vinca alkaloid treatments. Both patients treated with vinca alkaloids for severe hemolysis responded. Two patients received oral cyclosporin for refractory ITP; one had a transient response. Splenectomy was not included in our regimen. Two patients underwent splenectomy prior to their referral; both required further therapy. In addition, review of the clinical courses of our patients indicate that the DAT may be a prognostic factor for the chronicity of ITP.
CONCLUSION: In view of the high relapse rates after splenectomy and the encouraging results of our pilot study, we suggest that medical treatment with combination agents (IVIG, steroids, vinca alkaloids, androgens and possibly cyclosporin) may provide a useful therapeutic approach to patients with Evans syndrome.
PATIENTS AND METHODS: Five patients with Evans syndrome were followed for a median of 3.8 years and were treated according to our multiagent (IVIG, steroids, vinca alkaloids, androgens, and cyclosporin) protocol.
RESULTS: All patients initially received IVIG and IV steroids for either acute hemolysis or thrombocytopenia. IV vinca alkaloids and oral Danazol were added in three patients for ITP. All responded, but two required frequently repeated vinca alkaloid treatments. Both patients treated with vinca alkaloids for severe hemolysis responded. Two patients received oral cyclosporin for refractory ITP; one had a transient response. Splenectomy was not included in our regimen. Two patients underwent splenectomy prior to their referral; both required further therapy. In addition, review of the clinical courses of our patients indicate that the DAT may be a prognostic factor for the chronicity of ITP.
CONCLUSION: In view of the high relapse rates after splenectomy and the encouraging results of our pilot study, we suggest that medical treatment with combination agents (IVIG, steroids, vinca alkaloids, androgens and possibly cyclosporin) may provide a useful therapeutic approach to patients with Evans syndrome.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app